Sirtex, a global healthcare business with offices in the United States, Australia, Europe and Asia, announced on Monday that it has successfully performed the first procedure of selective internal radiation therapy using SIR-Spheres Y-90 resin microspheres for a patient with hepatocellular carcinoma in China, effective 28 September 2021.
The company has achieved this milestone with the support of its shareholder China Grand Pharmaceutical and Healthcare Holdings Limited.
Dr Jiahong Dong, a specialist in hepatobiliary pancreatic surgery and liver transplantation, and his team at Boao Super Hospital in the Hainan Province have carried out the procedure.
In November 2020, the National Medical Products Administration (NMPA) of the People's Republic of China accepted the Sirtex new drug application (NDA) of SIR-Spheres Y-90 resin microspheres for the treatment of colorectal cancer liver metastases.
Tavros Therapeutics collaborates with OpenBench for cancer treatment
ONA Therapeutics names new independent chair of board
MingMed Biotechnology's Investigational New Drug application for PRJ1-3024 receives US FDA approval
SQZ Biotechnologies Accepted by Roche Accelerator in China
Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research
Gilead, AWS Collaborate on Development and Delivery of New Medicines for Patients
Endra Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology
Chamberlain Named Chief Executive Officer of Neomorph
Immunome Submits Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19